• bioAffinity Technologies will present new research data at CHEST 2026 on investigational sputum-based tests for asthma and COPD inflammation.
• Study findings indicate the approach can detect multiple inflammation-related biomarkers, aiming to profile patients for precision monitoring over time.
• Work uses the company’s flow cytometry and AI platform, extending technology used in its CyPath Lung diagnostic into inflammatory lung disease.
• Presentation scheduled for Oct. 20, 2026 in Phoenix, with a related clinician-focused discussion set for Oct. 21.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261013780632) on October 13, 2026, and is solely responsible for the information contained therein.